Description
PKI-402 is an inhibitor of PI3K that is somewhat selective for p110α; it also inhibits mTORC1/2. PKI-402 exhibits anticancer chemotherapeutic activity, inhibiting cell proliferation in vitro and suppressing tumor growth induced by a variety of cancer cells in vitro, such as breast cancer, glioma, and pancreatic cancer.